In this randomized controlled clinical trial, defined cases of COVID-19 with mild, moderate, or severe pneumonia (according to the NIH guideline) were treated with conventional treatment regimens (controls) as well as in combination with oral administration of colchicine plus herbal phenolic monoterpene fractions (intervention arm). After randomization, each group received the mentioned treatments and were evaluated for different variables including mortality, hospitalization duration, intensive care unit (ICU) administration ratios as well as laboratory variables such as leukocytes and lymphocytes count. The follow-up period considered as 2 weeks after discharge. The mentioned variables were assessed as before and after receiving the treatment in each group as well as intergroup analysis for comparing both baseline and final values.
This section will be uploaded.
Drug: Standard Treatment
Standard Treatment for COVID-19 based on National Recommendations
Drug: Oral administration of Colchicine plus Herbal Phenolic Monoterpene Fractions
Colchicine plus a Herbal extraction containing a Phenolic Monoterpene Fractions will be added to standard treatment in patients with COVID-19.
Inclusion Criteria:
- Defined cases of COVID-19 based on laboratory and/or radiological and clinical
manifestation
Exclusion Criteria:
- Age <10, Pregnancy, Sever kidney dysfunction, Previous history of allergy to
Colchicine, not willing to sign informed consent form
Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
Kermanshah, Iran, Islamic Republic of
Ali Mostafaie, PhD, Principal Investigator
Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.